JP2023524230A5 - - Google Patents
Info
- Publication number
- JP2023524230A5 JP2023524230A5 JP2022565835A JP2022565835A JP2023524230A5 JP 2023524230 A5 JP2023524230 A5 JP 2023524230A5 JP 2022565835 A JP2022565835 A JP 2022565835A JP 2022565835 A JP2022565835 A JP 2022565835A JP 2023524230 A5 JP2023524230 A5 JP 2023524230A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- stereoisomer
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018427P | 2020-04-30 | 2020-04-30 | |
| US63/018,427 | 2020-04-30 | ||
| PCT/CN2021/090718 WO2021219040A1 (en) | 2020-04-30 | 2021-04-28 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524230A JP2023524230A (ja) | 2023-06-09 |
| JP2023524230A5 true JP2023524230A5 (enExample) | 2023-11-07 |
| JP7748392B2 JP7748392B2 (ja) | 2025-10-02 |
Family
ID=78373345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565835A Active JP7748392B2 (ja) | 2020-04-30 | 2021-04-28 | 腫瘍微小環境における免疫調節のためのヒストンデアセチラーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11672788B2 (enExample) |
| EP (1) | EP4142733B1 (enExample) |
| JP (1) | JP7748392B2 (enExample) |
| KR (1) | KR20230005939A (enExample) |
| CN (1) | CN116033904A (enExample) |
| AU (1) | AU2021265994B2 (enExample) |
| BR (1) | BR112022022015A2 (enExample) |
| ES (1) | ES3051512T3 (enExample) |
| HR (1) | HRP20251279T1 (enExample) |
| IL (1) | IL297687A (enExample) |
| MX (1) | MX2022013634A (enExample) |
| PL (1) | PL4142733T3 (enExample) |
| TW (1) | TWI849310B (enExample) |
| WO (1) | WO2021219040A1 (enExample) |
| ZA (1) | ZA202212650B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322171B (zh) * | 2022-08-30 | 2023-03-17 | 深圳微芯生物科技股份有限公司 | 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物 |
| CN122036601A (zh) * | 2024-11-15 | 2026-05-15 | 深圳微芯生物科技股份有限公司 | 一种苯甲酰胺类衍生物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| EP1641458A2 (en) | 2002-12-27 | 2006-04-05 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
| CA2552279C (en) * | 2003-12-02 | 2014-07-15 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
| CA2702536A1 (en) | 2007-10-10 | 2009-04-16 | Orchid Research Laboratories Limited | Novel histone deacetylase inhibitors |
| CN106916100B (zh) * | 2014-04-04 | 2020-09-15 | 深圳微芯生物科技股份有限公司 | 一种e构型苯甲酰胺类化合物及其药用制剂 |
| CN106916101B (zh) | 2017-02-15 | 2020-05-01 | 聚缘（上海）生物科技有限公司 | Nampt/hdac双靶点抑制剂及其制备方法 |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
-
2021
- 2021-04-28 HR HRP20251279TT patent/HRP20251279T1/hr unknown
- 2021-04-28 MX MX2022013634A patent/MX2022013634A/es unknown
- 2021-04-28 WO PCT/CN2021/090718 patent/WO2021219040A1/en not_active Ceased
- 2021-04-28 JP JP2022565835A patent/JP7748392B2/ja active Active
- 2021-04-28 BR BR112022022015A patent/BR112022022015A2/pt not_active Application Discontinuation
- 2021-04-28 PL PL21796395.8T patent/PL4142733T3/pl unknown
- 2021-04-28 AU AU2021265994A patent/AU2021265994B2/en active Active
- 2021-04-28 ES ES21796395T patent/ES3051512T3/es active Active
- 2021-04-28 KR KR1020227042007A patent/KR20230005939A/ko active Pending
- 2021-04-28 EP EP21796395.8A patent/EP4142733B1/en active Active
- 2021-04-28 IL IL297687A patent/IL297687A/en unknown
- 2021-04-28 TW TW110115446A patent/TWI849310B/zh active
- 2021-04-28 US US17/243,378 patent/US11672788B2/en active Active
- 2021-04-28 CN CN202180031935.4A patent/CN116033904A/zh active Pending
-
2022
- 2022-11-21 ZA ZA2022/12650A patent/ZA202212650B/en unknown
-
2023
- 2023-05-01 US US18/310,387 patent/US12213971B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507938A5 (enExample) | ||
| JP2017088633A5 (enExample) | ||
| JP2024521979A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2004525908A5 (enExample) | ||
| JP2012508249A5 (enExample) | ||
| JP2006501176A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2008503515A5 (enExample) | ||
| JP2017526675A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| JP2017524735A5 (enExample) | ||
| JP2015510886A5 (enExample) | ||
| BR112016002496B1 (pt) | Composto e composição farmacêutica | |
| JP2014510149A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| AU2016325643A1 (en) | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type | |
| JP2022188265A (ja) | ヒストンデアセチラーゼ阻害剤とｂｃｌ－２阻害剤とを含む医薬品配合物、及びそれらの使用方法 | |
| SG11202111402PA (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| JP2009511508A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2015520770A5 (enExample) | ||
| JP2017526662A5 (enExample) |